Home › Funds › D. E. Shaw & Co., Inc. › EXEL
D. E. Shaw & Co., Inc. position in EXEL
EXELIXIS INC · Health Care
D. E. Shaw & Co., Inc. reported holding 5,551,747 shares of EXEL (EXELIXIS INC) in its Q2 2026 13F filing — a position valued at US$302.1M, representing 0.43% of its reported portfolio and ranking #27 among its reported holdings. D. E. Shaw & Co., Inc. has disclosed EXEL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How D. E. Shaw & Co., Inc.'s EXEL position evolved
D. E. Shaw & Co., Inc. first disclosed a stake in EXEL in Q3 2023 at 1,499,596 shares (US$32.8M). The position peaked in Q2 2026 at 5,551,747 shares, worth US$302.1M. Across 12 filings, D. E. Shaw & Co., Inc. increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 5,551,747 shares valued at US$302.1M — an increase of 1,948,684 shares quarter over quarter.. Notable position changes include a 131% increase in Q3 2024 (shares rose 28% over the following quarter), a 725% increase in Q4 2025 (shares fell 3% over the following quarter), a 94% increase in Q1 2026 (shares rose 28% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.50M | $32.77M | New |
| Q4 2023 | 854.14K | $20.49M | Reduce |
| Q1 2024 | 529.49K | $12.56M | Reduce |
| Q2 2024 | 564.07K | $12.67M | Add |
| Q3 2024 | 1.30M | $33.76M | Add |
| Q4 2024 | 1.62M | $54.00M | Add |
| Q1 2025 | 712.58K | $26.31M | Reduce |
| Q2 2025 | 603.36K | $26.59M | Reduce |
| Q3 2025 | 225.43K | $9.31M | Reduce |
| Q4 2025 | 1.86M | $81.52M | Add |
| Q1 2026 | 3.60M | $154.54M | Add |
| Q2 2026 | 5.55M | $302.07M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EXEL and 13F data
EXEL (EXELIXIS INC) is a Health Care company. 41 other funds we track also report a position in EXEL — the largest reported positions include Farallon Capital Management (US$732.8M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$732.8M), Renaissance Technologies (US$730.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EXEL
- Farallon Capital Management 13.47M sh · $732.79M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 13.47M sh · $732.79M · Q2 2026
- Renaissance Technologies 13.43M sh · $730.62M · Q2 2026
- FULLER & THALER ASSET MANAGEMENT, INC. 8.93M sh · $485.85M · Q2 2026
- Two Sigma Investments 4.21M sh · $229.06M · Q2 2026
- Stephens Investment Management Group LLC 2.71M sh · $147.45M · Q2 2026
- Caligan Partners LP 1.55M sh · $84.51M · Q2 2026
More on D. E. Shaw & Co., Inc.
FAQ
How long has D. E. Shaw & Co., Inc. held EXEL?
D. E. Shaw & Co., Inc. has disclosed EXEL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is D. E. Shaw & Co., Inc.'s current position in EXEL?
As of Q2 2026, D. E. Shaw & Co., Inc. holds 5.55M shares of EXEL (EXELIXIS INC), valued at $302.07M, representing 0.43% of its reported portfolio and ranking #27.
Has D. E. Shaw & Co., Inc. been buying or selling EXEL?
In the latest 13F filing (Q2 2026), D. E. Shaw & Co., Inc. increased its position in EXEL. The position peaked in Q2 2026 at 5.55M shares.
Which other funds hold EXEL?
Other major institutional holders of EXEL include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., Renaissance Technologies, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.